mardi 21 avril 2020

Onco Actu du 21 avril 2020


1. BIOLOGIE



Finding leukemia's weakness using genome-wide CRISPR technology [UC San Diego]











3.4.1 CHIMIOPRÉVENTION - ASPIRINE



Daily Aspirin Tied to Lower Risk of Various Digestive Cancers [NY Times]











4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS



Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer [Roche]











5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS



Positive data keep Bristol Myers and Exelixis in the kidney cancer race [Biopharma Dive]











Bristol Myers Squibb and Exelixis Announce Positive Topline Results from Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Previously Untreated Advanced Renal Cell Carcinoma [BMS]











Exelixis lands PhIII kidney cancer win with Bristol Myers in their hunt for $4 billion [EndPoints]










5.12.4 IMMUNOTHÉRAPIES - ESSAIS



Bristol Myers Squibb's Opdivo-Yervoy combo helps mesothelioma patients live longer [Fierce Pharma]











Bristol Myers Squibb Announces Positive Topline Result from Pivotal Phase 3 Trial Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) vs. Chemotherapy in Previously Untreated Malignant Pleural Mesothelioma [BMS]











5.3.4.1 TRAITEMENTS - AMM (FDA, EMA,...) - PEMIGATINIB



Incyte beefs up portfolio with FDA nod for rare bile duct cancer therapy Pemazyre [Fierce Pharma]











FDA Approves Incyte Drug, First Ever for Rare Bile Duct Cancer [Xconomy]











6.1 OBSERVATION



Breastfeeding May Lower Risk of Ovarian Cancer [NY Times]










6.15 LUTTE CONTRE LES CANCERS - COVID-19



How coronavirus is impacting cancer services in the UK [Cancer Research UK]











Cancer and COVID-19; how do we manage cancer optimally through a public health crisis? [European Journal of Cancer]










COVID-19: impact on cancer workforce and delivery of care [Lancet Oncology]